Udenyca® (pegfilgrastim-cbqv)

aBL 761039

Udenyca® (pegfilgrastim-cbqv)

aBL 761039

U.S. License Holder:

Coherus

Date of License:

November-02-2018

Last Update:

February-28-2021

approved_indications FDA-Approved Indications

UDENYCA (pegfilgrastim-cbqv) is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

approved_indications Approved Foreign Follow-On Biologics / Biosimilars

Biosimilars Approved In The E.U.

Udenyca® (Coherus Biosciences) (September-2018)

approved_indications U.S. Patent Litigations

PACER

Case No(s):

1:17-cv-00546 (D. Del.)

U.S. Patent Nos.
8,273,707 (Process for Purifying Proteins)

Plaintiffs
Amgen Inc.; Amgen Manufacturing, Ltd.

Defendants
Coherus Biosciences Inc.

Federal Circuit Appeal(s)
18-1993

Status
Dismissed for Failure to State a Claim; Federal Circuit Affirmed

BPCIA
Y

56-2017-00493553-CU-BT-VTA (CA Sup. Ct.)

U.S. Patent Nos.
[None Listed]

Plaintiffs
Amgen Inc.

Defendants
Coherus Biosciences Inc.

Status
Settled

BPCIA
N

related articles Related News Articles

Venable Fitzpatrick’s BiologicsHQ Monthly Injection – January 2021 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong February 8, 2021
Spotlight On: Neulasta® (pegfilgrastim) / Fulphila® (pegfilgrastim-jmdb) / Udenyca® (pegfilgrastim-cbqv) / Ziextenzo® (pegfilgrastim-bmez) / Nyvepria™ (pegfilgrastim-apgf) April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D. January 31, 2021
Spotlight On: Biosimilar Litigations April Breyer Menon; Ha Kung Wong January 31, 2021
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – December 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong January 12, 2021
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – November 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong December 9, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – October 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong November 9, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – September 2020 April Breyer Menon; Damineh Morsali, Ph.D.; Robert S. Schwartz, Ph.D.; Ha Kung Wong October 8, 2020
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – January 2019 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. February 11, 2019
Venable Fitzpatrick’s BiologicsHQ Monthly Injection – November 2018 April M. Breyer Menon; Corinne E. Atton; Robert S. Schwartz, Ph.D. December 11, 2018

Methodology

Information contained in the Venable Fitzpatrick BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable Fitzpatrick BiologicsHQ database.

Disclaimer

The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

Subscribe for Future Updates

    captcha